This can’t be good. Teligent Inc. has announced the recall of two of its drugs. These consisted of:
two lots of topical lidocaine solution after companies testing the drug received superpotent (sic) results at the nine-month and 18-month stability time points. The company faced similar problems in September, and it had a number of run-ins with the FDA prior to that.Fierce Pharma – December 8, 2021
For a company already in bankruptcy – as discussed in our prior article when we initiated coverage – this is yet another setback. For the only BDC with exposure – Ares Capital (ARCC) – this means the prospect of even higher losses when the company’s future fortunes are settled. We “cut to the chase” in our earlier post and suggested that a complete write-off was a possibility, meaning that ARCC might take a further ($34.5mn) write-down and a realized loss of ($73.8mn). For the BDC, which is trying to buy the company out of bankruptcy and has just funded $12mn in new financing, this news could not come at a worst time, we imagine.
We continue to carry Teligent as CCR 5 and Trending in that we expect the next valuation in the IVQ 2021 could be materially lower than as of September 30, 2021.